Genome & Co. Files Amendment to Stock Option Grant (Reduced Grantees and Shares)

Genome & Company submitted an amendment to the stock option grant report (May 14, 2026)
Grantees reduced from 53 to 50, shares granted reduced from 1,235,908 to 1,211,108 (due to resignation, settlement, forfeiture)
Exercise price unchanged at 2,560 won; total outstanding options post-grant: 4,092,568 (previously 4,843,300)
Changes in fair value assumptions: risk-free rate 2.37~3.16%, expected volatility 68.33% (previously 2.622% and 76.84%)
Exercise period: March 29, 2027 to March 28, 2034